Morphological changes in intraretinal microvascular abnormalities after anti-VEGF therapy visualized on optical coherence tomography angiography
Authors:
Open Access
- 1 June 2020
- journal article
- research article
- Published by Springer Nature in Eye and Vision
- Vol. 7 (1) , 1-9
Abstract
Background: To examine the baseline morphological characteristics and alterations in intraretinal microvascular abnormalities (IRMAs) in response to anti-vascular endothelial growth factor (anti-VEGF) treatment, documented by optical coherence tomography angiography (OCTA) in diabetic eyes. Methods: In this retrospective study, IRMAs were evaluated with multimodal imaging (fundus photography, fluorescein angiography, OCTA) in treatment-naïve diabetic eyes before and after anti-VEGF treatment for diabetic macular edema (DME) and/or proliferative diabetic retinopathy (PDR) and compared to diabetic control eyes with similar diabetic retinopathy (DR) severity that did not receive anti-VEGF therapy. The morphological characteristics of IRMAs on enface OCTA imaging were graded by masked readers at baseline, then after anti-VEGF therapy in treated eyes or after observation in control eyes. Characterization of interval changes in an IRMA were based on the following parameters: branching, vessel caliber and area of adjacent capillary non-perfusion. Results: The treated group included 45 IRMA foci from 15 eyes of 11 patients, while the control group included 27 IRMA foci from 15 eyes of 14 patients. Following anti-VEGF treatment, enface OCTA demonstrated that 14 foci of IRMA (31%) demonstrated regression with normalization of appearance of the capillary bed, 20 IRMAs (44%) remained unchanged, six IRMAs (13%) progressed with enlargement or development of new IRMAs and five IRMAs (11%) demonstrated complete obliteration defined as IRMA disappearance with advancing capillary drop-out. In the control group, 17 IRMA (63%) remained stable, 8 IRMAs (29.6%) progressed and 2 experienced total obliteration (7.4%). The difference in rank order between the two groups was statistically significant (p = 0.022). Conclusions: In eyes with DR status post anti-VEGF therapy, foci of IRMAs have a variable course demonstrating one of four possible outcomes: regression, stability, progression or complete obliteration. In contrast, none of the untreated control diabetic eyes demonstrated regression of IRMAs, consistent with known progression of DR severity in high risk eyes. Morphologic evaluation of IRMAs with OCTA may help to monitor changes in retinal blood flow as well as the response to anti-VEGF treatment.Keywords
This publication has 28 references indexed in Scilit:
- Ranibizumab for Diabetic Macular EdemaOphthalmology, 2012
- Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease?British Journal of Ophthalmology, 2012
- Effects of Macular Ischemia on the Outcome of Intravitreal Bevacizumab Therapy for Diabetic Macular EdemaRetina, 2008
- Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scalesOphthalmology, 2003
- Histopathology of diabetic retinopathy in manEye, 1993
- Fundus Photographic Risk Factors for Progression of Diabetic RetinopathyOphthalmology, 1991
- Early Treatment Diabetic Retinopathy Study Design and Baseline Patient CharacteristicsOphthalmology, 1991
- Reflow of obstructed capillaries in the maculae of humans with diabetic retinopathy, observed by fluorescein angiography.British Journal of Ophthalmology, 1988
- Retinal revascularisation in diabetic retinopathy.British Journal of Ophthalmology, 1986
- Arteriolar Involvement in Diabetic RetinopathyBritish Journal of Ophthalmology, 1953